
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. is experiencing a positive outlook primarily due to the successful clinical performance of lorundrostat, its oral selective aldosterone synthase inhibitor, which has demonstrated robust blood pressure reductions of 8-12 mmHg in patients with resistant hypertension. The pivotal Launch-HTN Phase 3 trial results indicate significant effectiveness, with a placebo-adjusted reduction of 9.1 mmHg at six weeks and 11.7 mmHg at twelve weeks, combined with a low hyperkalemia rate, highlighting the candidate's favorable safety profile. This strong clinical data supports a strategic opportunity for lorundrostat's daily use in uncontrolled hypertension, positioning Mineralys favorably in the biopharmaceutical market.
Bears say
Mineralys Therapeutics Inc. reported a significant net loss of $48.9 million for the fourth quarter of 2024, translating to a loss of $0.98 per share, and a total net loss of $177.8 million for the full year, at $3.66 per share. Key risks contributing to a negative outlook include the potential failure of lorundrostat to achieve expected peak commercial revenue due to market size, penetration rates, and pricing dynamics. Additionally, the company's ability to secure necessary capital for ongoing operations and the continued development and commercialization of its programs remains uncertain, further compounding the investment risks.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares